ArticleCell reports. Medicine2026

Enfortumab vedotin induces immunogenic cell death and shows enhanced preclinical antitumor activity when combined with a PD-1 inhibitor.

Devra J Olson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.